NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Andy, Dr. Bota's comment that 24.7% of the patients lived longer than 7 years does not mean that 24.7% of the 331 patients in the DCVax-L trial lived that long.

Dr. Bota probably misspoke and should have said that 24.2% (not 24.7%) of the first 182 patients in the DCVax-L trial (44 patients) lived 36(+) months and that the estimated mOS of those 44 was 88.2 months, hence more than 7 years.

That means that 22 of the first 182 patients or 12% would survive past 7 years. Given that the group of 149 patients that followed the first group of 182, demonstrated at 36 months on trial, a superior survival capacity (about a 32.9% survival at 36 months), the fraction of the 331 patients surviving past 7 years would most likely be a little higher than 12%.

Dr. Bota also mentioned that in her trial both early as well as late Treatment patients would do very very well whereas sometimes ago Dr. Liau emphasized the importance of early administration of L. This suggests to me that Dr. Liau believes that the Treatment patients in our trial will demonstrate a better survival capacity than the control patients who after progression crossed over.